title: Response to beta blockers in patients with neurocardiogenic syncope: how to predict beneficial effects.
abstract: No definitive data are available about the possibility of predicting improvement in patients with neurocardiogenic syncope treated with beta blockers. Among 112 patients with syncope and a positive head-up tilt test (HUT), independent predictors for prevention of symptoms with beta blockers were determined using the Cox proportional hazards model. Each patient underwent HUT at 70 degrees for 20 minutes both in the drug-free state and during isoproterenol infusion given to increase the heart rate by at least 25%. Fifty-nine patients had a positive HUT during isoproterenol infusion and 53 in the drug-free state. All patients were then given esmolol infusion at 500 micrograms/kg per minute for 3 minutes followed by 300 micrograms/kg per minute maintenance dose. HUT was then repeated as previously described with or without isoproterenol, depending upon the initial positive response. Regardless of the response during esmolol, all patients were treated with metoprolol 50 to 100 mg twice daily. At follow-up, 36 patients experienced symptom relapse. Four of them had negative HUT on esmolol, whereas the remaining 32 did not respond to the acute infusion of esmolol. Only four patients with positive HUT on esmolol had a favorable response to metoprolol. Patients responding to metoprolol were older (55 +/- 12 years vs 42 +/- 15 years, P < 0.05). Response to metoprolol was predicted by a negative test on esmolol (P < 0.0001) and a positive HUT on isoproterenol (P < 0.001). Age older than 42 years was also associated with a higher likelihood of metoprolol success (P < 0.02).
  
  
  CONCLUSIONS
  Acute challenge with esmolol infusion appears to be an accurate predictor of response to chronic beta blockers, together with age and a positive HUT during low-dose isoproterenol infusion.
authors.affiliation: Durham VA Medical Center, NC 27705, USA.
authors.forename: A
authors.initials: A
authors.lastname: Natale
authors.forename: K H
authors.initials: KH
authors.lastname: Newby
authors.forename: A
authors.initials: A
authors.lastname: Dhala
authors.forename: M
authors.initials: M
authors.lastname: Akhtar
authors.forename: J
authors.initials: J
authors.lastname: Sra
mesh_terms: D000318:Adrenergic beta-Agonists / Q000008:administration & dosage; D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D000328:Adult; D004562:Electrocardiography; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007262:Infusions, Intravenous; D007545:Isoproterenol / Q000008:administration & dosage; D008297:Male; D008790:Metoprolol / Q000008:administration & dosage / Q000627:therapeutic use*; D008875:Middle Aged; D011187:Posture; D011412:Propanolamines / Q000008:administration & dosage / Q000627:therapeutic use*; D012008:Recurrence; D019462:Syncope, Vasovagal / Q000175:diagnosis / Q000503:physiopathology / Q000517:prevention & control*; D016896:Treatment Outcome
chemical_list: D000318:Adrenergic beta-Agonists; D000319:Adrenergic beta-Antagonists; D011412:Propanolamines; D008790:Metoprolol; D007545:Isoproterenol; C036604:esmolol